Importer of Controlled Substances Application: S & B Pharma, Inc., 31421 [2018-14396]
Download as PDF
<![CDATA[
31421
Federal Register / Vol. 83, No. 129 / Thursday, July 5, 2018 / Notices
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405A,
Washington, DC 20530.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 6, 2018. Such persons
may also file a written request for a
hearing on the application on or before
August 6, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
DATES:
Dated: June 29, 2018.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2018–14413 Filed 7–3–18; 8:45 am]
BILLING CODE 4410–14–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: S & B Pharma, Inc.
ACTION:
Notice of application.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on June 6,
2018, S & B Pharma, Inc. DBA NORAC
Pharma, 405 S Motor Avenue, Azusa,
California 91702 applied to be registered
as an importer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
4-Anilino-N-phenethyl-4-piperidine (ANPP) .............................................................................................................
Tapentadol ...............................................................................................................................................................
The company plans to import the
controlled substances in bulk for the
manufacture of other controlled
substances for its customers. Tapentadol
(9780) will be imported in Intermediate
form to bulk manufacture Tapentadol
for distribution to its customers. No
other activity for these drug codes will
be allowed.
Dated: June 26, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–14396 Filed 7–3–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Methylene
Chloride Standard
Notice of availability; request
for comments.
amozie on DSK3GDR082PROD with NOTICES1
ACTION:
The Department of Labor
(DOL) is submitting the Occupational
Safety and Health Administration
(OSHA) sponsored information
collection request (ICR) titled,
‘‘Methylene Chloride Standard,’’ to the
SUMMARY:
VerDate Sep<11>2014
16:43 Jul 03, 2018
Jkt 244001
Office of Management and Budget
(OMB) for review and approval for
continued use, without change, in
accordance with the Paperwork
Reduction Act of 1995 (PRA). Public
comments on the ICR are invited.
DATES: The OMB will consider all
written comments that agency receives
on or before August 6, 2018.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov website at https://
www.reginfo.gov/public/do/PRA
ViewICR?ref_nbr=201805-1218-003 or
by contacting Michel Smyth by
telephone at 202–693–4129, TTY 202–
693–8064, (these are not toll-free
numbers) or by email at DOL_PRA_
PUBLIC@dol.gov.
Submit comments about this request
by mail to the Office of Information and
Regulatory Affairs, Attn: OMB Desk
Officer for DOL–OSHA, Office of
Management and Budget, Room 10235,
725 17th Street NW, Washington, DC
20503; by Fax: 202–395–5806 (this is
not a toll-free number); or by email:
OIRA_submission@omb.eop.gov.
Commenters are encouraged, but not
required, to send a courtesy copy of any
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
8333
9780
Schedule
II
II
comments by mail or courier to the U.S.
Department of Labor-OASAM, Office of
the Chief Information Officer, Attn:
Departmental Information Compliance
Management Program, Room N1301,
200 Constitution Avenue NW,
Washington, DC 20210; or by email:
DOL_PRA_PUBLIC@dol.gov.
FOR FURTHER INFORMATION CONTACT:
Michel Smyth by telephone at 202–693–
4129, TTY 202–693–8064, (these are not
toll-free numbers) or by email at DOL_
PRA_PUBLIC@dol.gov.
SUPPLEMENTARY INFORMATION: This ICR
seeks to extend PRA authority for the
Methylene Chloride Standard
information collection codified in
regulations 29 CFR 1910–1052. The
purpose of the Standard and its
information collection requirements is
to protect workers from the adverse
health effects that may result from their
exposure to MC. The requirements in
the Standard include: Worker exposure
monitoring, notifying workers of their
MC exposures, administering medical
examinations to workers, providing
examining physicians with specific
program and worker information,
ensuring that workers receive a copy of
their medical examination results,
maintaining workers’ exposure
monitoring and medical examination
records for specific periods, and
E:\FR\FM\05JYN1.SGM
05JYN1
]]>Agencies
[Federal Register Volume 83, Number 129 (Thursday, July 5, 2018)]
[Notices]
[Page 31421]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14396]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: S & B Pharma, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before August 6, 2018. Such
persons may also file a written request for a hearing on the
application on or before August 6, 2018.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.34(a), this is notice that on June
6, 2018, S & B Pharma, Inc. DBA NORAC Pharma, 405 S Motor Avenue,
Azusa, California 91702 applied to be registered as an importer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
4-Anilino-N-phenethyl-4- 8333 II
piperidine (ANPP).
Tapentadol...................... 9780 II
------------------------------------------------------------------------
The company plans to import the controlled substances in bulk for
the manufacture of other controlled substances for its customers.
Tapentadol (9780) will be imported in Intermediate form to bulk
manufacture Tapentadol for distribution to its customers. No other
activity for these drug codes will be allowed.
Dated: June 26, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-14396 Filed 7-3-18; 8:45 am]
BILLING CODE 4410-09-P
